Gastrointestinal Cancer

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

Elraglusib plus gemcitabine and nab-paclitaxel lead to an OS benefit vs chemotherapy alone in treatment-naive metastatic PDAC.

Panelists discuss how patient adherence to kinase inhibitors is crucial for disease control, requiring proactive adverse effect management, careful radiological monitoring, and strategies such as dose escalation to maximize treatment duration and effectiveness.

Panelists discuss how standard-of-care treatment follows NCCN guidelines with sequential kinase inhibitor therapy (imatinib, sunitinib, regorafenib, ripretinib), emphasizing that maintaining some form of kinase inhibition is always preferable to no treatment even after progression.

The NMPA of China has accepted the new drug application for satricabtagene autoleucel in pretreated gastric/GEJ cancer.

Michele Reni, MD, discusses the efficacy of pre-operative PAXG compared with modified FOLFIRINOX in stage I to III PDAC.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, detail the continued interest in RAS inhibition for pancreatic ductal adenocarcinoma.

Yelena Y. Janjigian, MD, discussed results from the MATTERHORN study of durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer.

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

The EMA’s CHMP has recommended the approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Panelists discuss how mutational testing is critical for gastrointestinal stromal tumor (GIST) management, with different genetic alterations determining treatment sensitivity and the importance of understanding both primary drivers and secondary resistance mutations that develop over time.

Panelists discuss how gastrointestinal stromal tumors (GISTs) are the most common sarcoma with specific genetic mutations, requiring comprehensive mutational analysis to guide treatment decisions and understand both primary and secondary resistance patterns.

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Atebimetinib plus gemcitabine/nab-paclitaxel produced signals of survival benefits in first-line pancreatic cancer.

Elena Elimova, MD, discusses the efficacy of zanidatamab with chemotherapy in HER2-positive advanced gastroesophageal adenocarcinoma.

CHM CDH17 has received fast track designation from the FDA for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Daneng Li, MD, discusses the IL-27–targeted agent casdozokitug in hepatocellular carcinoma.

Daneng Li, MD, discusses the efficacy and safety findings of a casdozokitug-based regimen in unresectable, advanced HCC.

Fruquintinib plus chemotherapy and a PD-1 inhibitor was safe and effective in patients with untreated HER2-negative advanced gastric/GEJ cancer.

The addition of disitamab vedotin to toripalimab and trastuzumab and/or CAPOX led to favorable response rates in HER2-expressing gastric/GEJ cancer.

EBC-129 monotherapy was active, generated responses, and had a manageable safety profile in heavily pretreated metastatic pancreatic ductal adenocarcinoma.

Neoadjuvant therapy with PAXG chemotherapy prolonged event-free survival vs mFOLFIRINOX in patients with stage I to III pancreatic ductal adenocarcinoma.

Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.

TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.

The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.